rilimogene galvacirepvec (Bavarian Nordic)

PROSTVAC V/F (rilimogene galvacirepvec) is a therapeutic cancer vaccine developed by Bavarian Nordic for the treatment of prostate cancer. It employs a heterologous prime-boost strategy using two different recombinant viral vectors: a vaccinia virus (PROSTVAC-V) for the initial priming dose and a fowlpox virus (PROSTVAC-F) for subsequent booster injections. Both vectors are engineered to express the prostate-specific antigen (PSA) with an L155 mutation to enhance T-cell recognition, along with a triad of human T-cell costimulatory molecules (B7.1, ICAM-1, and LFA-3), collectively known as TRICOM. The vaccine is designed to stimulate the immune system to recognize and destroy PSA-expressing prostate cancer cells. Although it demonstrated a survival benefit in Phase 2 trials, the pivotal Phase 3 PROSPECT trial in metastatic castration-resistant prostate cancer (mCRPC) failed to meet its primary endpoint of overall survival, leading to the discontinuation of its development for that specific indication as a monotherapy.

Other names

rilimogene galvacirepvecPROSTVACPSA-TRICOM